Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists
View Patent ↗Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ET B agonist IRL1620.
1. A method of contributing to the treatment of a lymphoma in a patient in need thereof, the method comprising:
administering a radiation sensitizer to the patient, wherein the radiation sensitizer is an IRL-1620, and wherein administration of the radiation sensitizer increases oxygenation of the lymphoma, thereby sensitizing the lymphoma to radiation-induced cellular damage; and
administering a radiation to the patient, wherein administration of the radiation induces cellular damage to the lymphoma, thereby treating the lymphoma in the patient;
wherein administration of the radiation sensitizer to the patient occurs before administration of the radiation to the patient.
2. The method according to claim 1 , wherein administration of the radiation sensitizer comprises systemic or local administration.
3. The method according to claim 2 , wherein administration of the radiation sensitizer occurs through a route selected from the group consisting of oral administration, intra-tumoral administration, intravenous administration, intravesical administration, intraarterial administration, intranasal administration, and a combination thereof.
4. A method for sensitizing lymphoma to radiation therapy in a patient in need thereof, the method comprising:
administering radiation sensitizer to the patient, wherein the radiation sensitizer is an IRL-1620; and wherein administration of the radiation sensitizer increases oxygenation of the lymphoma, thereby sensitizing the lymphoma to radiation-induced cellular damage; and
administering a radiation therapy to the patient, wherein increased cellular damage of the lymphoma due to the radiation therapy occurs due to the increased oxygenation resulting from administration of the radiation sensitizer;
wherein administration of the radiation sensitizer to the patient occurs before administration of the radiation therapy to the patient.
5. The method according to claim 4 , wherein administration of the radiation sensitizer comprises systemic or local administration.
6. The method according to claim 5 , wherein administration of the radiation sensitizer occurs through a route selected from the group consisting of oral administration, intra-tumoral administration, intravenous administration, intravesical administration, intraarterial administration, intranasal administration, and a combination thereof.